Glimepiride Teva Sante

Glimepiride Teva Sante is an oral tablet that contains the active ingredient glimepiride, a sulfonylurea class antidiabetic medication marketed in the European Union. It is supplied as a prescription product without a specific strength listed in this description. The tablet is designed to help manage blood glucose levels in adults with type 2 diabetes mellitus by stimulating insulin release from the pancreas and improve overall glycemic control.

Glimepiride Teva Sante is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve target glycaemic control.

- Used as monotherapy in patients with mild to moderate hyperglycaemia. - Added to metformin or other oral agents when additional glucose lowering is required. - May be considered in patients who have stable renal function and no history of severe hypoglycaemia. - Prescribed as part of a comprehensive diabetes management plan that includes lifestyle modification. - Utilised when clinicians aim for gradual reduction of HbA1c in conjunction with regular monitoring.

The safety profile of glimepiride includes a range of adverse events that are reported with varying frequency.

Common: - Low blood sugar (hypoglycaemia), especially when meals are missed. - Nausea or abdominal discomfort. - Headache or dizziness. - Weight gain.

Serious: - Severe hypoglycaemia leading to loss of consciousness. - Allergic reactions such as rash, itching, or swelling. - Liver enzyme elevations. - Blood disorders such as neutropenia or thrombocytopenia.

Before initiating Glimepiride Teva Sante, clinicians should evaluate several clinical factors to minimise risk.

- Assess renal and hepatic function; dose adjustment may be required in impairment. - Review history of cardiovascular disease, as sulfonylureas can affect cardiac ischemic preconditioning. - Avoid use in patients with known hypersensitivity to sulfonylureas. - Monitor for signs of hypoglycaemia, particularly in the elderly or those with irregular eating patterns. - Caution during pregnancy and lactation; the safety profile is not well established. - Consider potential impact on driving or operating machinery if hypoglycaemia occurs.

Glimepiride can interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid: - Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycaemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels.

Use with caution: - Beta‑blockers, which may mask hypoglycaemia symptoms. - Thiazide diuretics, which can affect blood glucose control. - ACE inhibitors or ARBs, as they may enhance hypoglycaemic risk. - Alcohol, which can potentiate hypoglycaemia.